Bank of New York Mellon Corp Acquires 13,285 Shares of Fluidigm Co. (FLDM)
Bank of New York Mellon Corp lifted its holdings in shares of Fluidigm Co. (NASDAQ:FLDM) by 3.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 383,712 shares of the medical research company’s stock after acquiring an additional 13,285 shares during the quarter. Bank of New York Mellon Corp owned about 0.99% of Fluidigm worth $2,260,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of FLDM. Levin Capital Strategies L.P. lifted its holdings in Fluidigm by 5.3% in the 4th quarter. Levin Capital Strategies L.P. now owns 9,167,070 shares of the medical research company’s stock worth $53,994,000 after buying an additional 463,310 shares in the last quarter. Neuberger Berman Group LLC lifted its holdings in Fluidigm by 181.6% in the 3rd quarter. Neuberger Berman Group LLC now owns 5,213,481 shares of the medical research company’s stock worth $26,276,000 after buying an additional 3,362,100 shares in the last quarter. State Street Corp lifted its holdings in Fluidigm by 6.2% in the 2nd quarter. State Street Corp now owns 499,524 shares of the medical research company’s stock worth $2,017,000 after buying an additional 29,110 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Fluidigm by 68.9% in the 4th quarter. Acadian Asset Management LLC now owns 146,705 shares of the medical research company’s stock worth $864,000 after buying an additional 59,839 shares in the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in Fluidigm in the 4th quarter worth $781,000. Institutional investors and hedge funds own 94.64% of the company’s stock.
FLDM has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Fluidigm from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 24th. ValuEngine lowered shares of Fluidigm from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Piper Jaffray reiterated a “hold” rating and issued a $6.10 price objective on shares of Fluidigm in a report on Thursday, February 8th.
Fluidigm (NASDAQ:FLDM) last issued its earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The company had revenue of $27.75 million during the quarter, compared to analyst estimates of $27.14 million. Fluidigm had a negative net margin of 59.38% and a negative return on equity of 118.56%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.32) EPS. sell-side analysts forecast that Fluidigm Co. will post -0.93 earnings per share for the current year.
In related news, insider Levin Capital Strategies, L.P. bought 6,871 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The shares were acquired at an average price of $6.57 per share, for a total transaction of $45,142.47. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders bought 622,144 shares of company stock worth $3,855,130. Company insiders own 4.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/04/17/bank-of-new-york-mellon-corp-acquires-13285-shares-of-fluidigm-co-fldm.html.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.